The role of Transforming growth factor beta (TGF-b) in carcinogenesis is complex. There are reports on both tumor inhibition and tumor promotion by TGF-b. To elucidate the complex role of TGF-b in epithelial carcinogenesis, we generated transgenic mice overexpressing a dominant negative type II TGF-b receptor in the basal cell compartment and in follicular cells of the skin. Despite the reduced responsiveness of transgenic keratinocytes to TGF-b, both proliferation and dierentiation were normal in non-irritated epidermis of these transgenic mice. Thus, interruption of signaling of all three isoforms of TGF-b in basal and follicular cells does not disturb tissue homeostasis. However, during tumor promotion transgenic mice showed an elevated level of proliferation in the epidermis. This hyperproliferation correlated with a very early onset of carcinoma development and a malignant conversion frequency of 30% from benign papillomas to carcinomas. By comparison, the conversion frequency in wild-type mice of this strain has previously been reported as 5.5%. Even without induction of hyperproliferation by tumor promoters, transgenic mice developed far more carcinomas as controls when treated with a carcinogen. This result indicates that there is a synergistic eect between loss of TGF-b responsiveness and mutations caused by initiation with a carcinogen leading to an endogeneous tumor promotion in initiated cells only.
Introduction
Transforming growth factor beta (TGF-b), the prototype of the large TGF-b-superfamily, which includes activin, inhibin, bone morphogenetic proteins (BMPs), MuÈ llerian inhibiting substance (MIS) and growth and dierentiation factors, plays an important role in dierentiation processes and in regulation of cell proliferation (Roberts and Sporn, 1990; Kingsley, 1994) . Therefore, TGF-b has also been implicated in epithelial carcinogenesis due to its various eects on epithelial cells. TGF-b is a potent negative growth regulator of epithelial cells and can alter their cellular phenotypes (Coey et al., 1988; Mansbridge and Hanawalt, 1988; Choi and Fuchs, 1990; Sellheyer et al., 1993) . Besides its expression in basal cells of normal epidermis TGF-b is induced in the suprabasal compartment of the epidermis in response to the tumor promoter 12-O-tetradecanoylphorbol-13-acetate, TPA (Akhurst et al., 1988; Pelton et al., 1991) . But the precise role of TGF-b in disturbed tissue homeostasis and carcinogenesis is discussed controversely. On one hand, it has been shown that TGF-b can have tumor suppressor activities most likely due to its growth inhibitory activity. Additionally, loss of TGF-b expression in benign skin papillomas is correlated with a high risk for malignant conversion (Missero et al., 1991; Glick et al., 1993; Cui et al., 1994; Glick et al., 1994) . On the other hand, TGF-b can also stimulate malignant progression, possibly by its action on cell-matrix interaction, by its immunosuppressive activities or by enhancing angiogenesis (Roberts et al., 1986; Torre-Amione et al., 1990; Arrick et al., 1992; Glick et al., 1994; Cui et al., 1996) . TGF-b conveys signals via two serine/threonine kinase receptors, type I and type II, both of which are necessary for signal transduction Derynck, 1994) . The type II TGF-b receptor determines ligand speci®city and is able to interact with dierent type I receptor isoforms (Attisano et al., 1993) . Unlike the type II receptor, type I receptors can only recognize ligand bound to the type II receptor which is then recruited to a complex (Ebner et al., 1993) . In this complex the serine/threonine kinase domain of the type II receptor phosphorylates serine residues in a serine-and glycine-rich region adjacent to the aminoterminal boundary of the kinase domain (GS domain) of the type I receptor. This phosphorylation step activates the kinase domain of type I receptor which can subsequently propagate the signal to downstream eectors Heldin et al., 1997) . Loss of TGF-b expression and resistance to the growth inhibition through TGF-b seems to be a late event in tumor progression (Haddow et al., 1991) . Mutations of the type II receptor can interrupt the signal transduction pathway by dominant negative mechanisms (Wrana et al., 1992; Brand et al., 1993; Carcamo et al., 1995) . Inactivation or reduced expression of the type II receptor has been shown to occur for example in colon cancer cells with microsatellite instability, in a cutaneous T-cell lymphoma, in various human breast tumor cell lines and in a retinoblastoma cell line (Kimchi et al., 1988; Kalkhoven et al., 1995; Markowitz et al., 1995; Knaus et al., 1996) . Thus, inactivation of the type II TGF-b receptor may provide a means for tumor cells to escape TGF-b mediated growth restriction. To elucidate the complex and contradictory role of TGF-b signaling in tumor progression, we subjected transgenic mice expressing a dominant negative mutant of the type II TGF-b receptor to skin carcinogenesis protocols (DiGiovanni, 1991; Brand et al., 1993; Hennings et al., 1993) . This approach has several advantages. It is possible to interfere with signal transduction of all three isotypes of TGF-b, TGF-b1, -b2, -b3 (Cheifetz et al., 1990; Sankar et al., 1995) . Furthermore, the tissue speci®c expression cassette targets transgene expression to speci®c tissues. Thereby, embryonic lethality as seen in the type II TGF-b receptor knockout mice is avoided (Oshima et al., 1996) . To direct the expression of the transgene to the basal compartment of the epidermis and to hair follicles we used a previously described expression cassette based on the bovine keratin 5 promoter (Blessing et al., 1993; Casatorres et al., 1994; Ramirez et al., 1994) . Expression of the transgene in non-irritated skin has no eects on skin homeostasis. But during tumor promotion, reduction of TGF-b responsiveness in transgenic skin leads to an extraordinary early onset of carcinoma development and an extremely high overall yield of malignant tumors.
Results
To interrupt the signal-transduction pathway for TGFb we used a dominant negative mutant of the type II receptor for TGF-b lacking the intracellular kinase domain (DkTbRII). We ligated the truncated cDNA of the type II TGF-b receptor to the previously characterized bovine keratin 5 promoter (Figure 1) , which drives the expression of a transgene in the basal compartment of the mouse epidermis and in follicular cells. In addition, the construct provided a splice-and polyadenylation-signal derived from the bovine keratin 5 gene located downstream of the cDNA insertion site. We obtained two founder animals, which were both fertile and gave rise to two transgenic lines, TgN (K5dkTbRII)54Mbl and TgN(K5dkTbRII)114Mbl, abbreviated as line 54 and line 114, respectively. Heterozygous animals of both lines showed no obvious abnormalties. Analysis of hematoxylin and eosin stained skin sections revealed a normal histology (data not shown). Furthermore, no aberrant expression patterns of the basal type keratin 14, the suprabasal dierentiation marker keratin 1 and 10 and the hyperproliferation marker keratin 6 were detected (data not shown).
Tissue speci®c transgene expression was analysed by Northern blot analysis (Figure 2a ± c) and RT-PCR analysis (Figure 2d ) with total RNA extracted from various tissues. A transgene speci®c cDNA of the human dominant negative type II TGF-b receptor was used as a hybridization probe. By Northern blot analysis, mice of both lines showed expression of the transgene in skin and in the respiratory tract (lung and trachea) with an overall stronger expression in mice of line 114. Additionally, this line showed a weak expression in kidney (Figure 2a ± c) . RT-PCR analysis revealed that beside the expression of the transgene in skin and in the respiratory tract it is also expressed in cervix and very weakly in tongue and stomach in mice of line 114 (Figure 2d ). The results of the RT-PCR analysis from RNAs of line 54 were comparable to the results shown for line 114 and no transgene speci®c PCR-product was obtained when RNAs from nontransgenic controls were used as templates (data not shown). The transgene speci®c RNA from mice of line 54 was markedly overexpressed in skin revealed by comparison of the endogeneous type II TGF-b receptor RNA to the transgene speci®c RNA ( Figure  2e ). Western blot analysis of protein extracts from primary keratinocytes of line 114 and non-transgenic keratinocytes, using an antibody against the human type II TGF-b receptor, detected a 44 kDA band only in the extracts from transgenic keratinocytes. This band represents the truncated human type II TGF-b receptor (Figure 2f ). The transgene-derived receptor is expressed in both transgenic lines whereby keratinocytes of line 54 showed a weaker protein expression (data not shown). This is consistent with the results of the Northern blot analysis (Figure 2a and b) . In situ hybridization experiments using a riboprobe derived from the 3' untranslated region of the bovine keratin 5 minilocus, demonstrated accumulation of transgenespeci®c RNA primarily in the basal epidermal layer and in the outer root sheath of hair follicles in mice of lines 114 and 54 ( Figure 3 and data not shown).
Cultured primary transgenic keratinocytes showed a reduced sensitivity to TGF-b
In order to con®rm the functionality of the dominant negative receptor, the ability of transgenic primary keratinocytes to escape the inhibitory eect of TGF-b on cell proliferation was examined. We isolated keratinocytes from newborn transgenic mice and from their non-transgenic littermates. The proliferation was measured by [ 3 H]-thymidine incorporation after preincubation with various concentrations of TGF-b for 24 h (Figure 4 ). Non-transgenic keratinocytes showed a high and dose dependent sensitivity to the growth inhibitory eect of TGF-b. The IC 50 was 0.075 ng/ml TGF-b1 for the non-transgenic keratinocytes, whereas in keratinocytes of line 114 the IC 50 was 0.67 ng/ml TGF-b1, i.e. ninefold higher. In keratinocytes of line 54 the IC 50 was 0.25 ng/ml TGF-b1, still over threefold higher compared to non-transgenic keratinocytes. The dierent eect of TGF-b1 on the growth rate of the transgenic keratinocytes correlates with the expression levels of the transgene as shown by Northern blot analysis. These results demonstrated that the dominant negative type II TGF-b receptor interferes with the signal-transduction pathway for TGF-b in primary keratinocytes.
Tumor induction in transgenic and non-transgenic mice
In order to investigate the in¯uence of TGF-b signaling in tumor development we subjected mice of both transgenic lines as well as control mice to dierent skin carcinogenesis protocols. In one experiment we initiated 25 mice per line and 24 non-transgenic littermates with DMBA and promoted with TPA for 20 weeks. Transgenic mice of both lines developed squamous cell carcinomas suprisingly early only after a few weeks of promotion ( Figure 5a ). In mice of line 114 the ®rst carcinoma was seen as early as 4 weeks after initiation. The percentage of mice developing carcinomas increased steadily, until 81% had developed one or more carcinoma at 20 weeks of promotion. Transgenic mice of line 54 had a similar early onset of carcinoma development with the ®rst malignant tumor appearing after 6 weeks of promotion. The percentage of mice with carcinomas in line 54 was lower during the ®rst 11 weeks of treatment compared to mice of line 114, however, again 81% of the transgenic mice carried carcinomas at the end of the experiment. In non-transgenic controls, no carcinomas arose during the ®rst 20 weeks of promotion ( Figure 5a and Table 1 ). Figure 5b shows the development of all tumors (papillomas and carcinomas combined). Transgenic mice formed more tumors at an earlier stage compared to control mice, which was especially obvious during the ®rst 10 weeks of promotion. After 20 weeks of promotion all mice of both transgenic lines and almost 90% of the control mice developed tumors. However, the frequency of malignant conversion was extremely high in both transgenic lines (Table 1) . Mice of line 114 and line 54 displayed conversion frequencies of 34% and of 31%, respectively, as compared to control mice with no conversion at all. The overall number of lesions, however, was similar in all three groups.
In a second experiment we investigated, if suppression of TGF-b signaling per se results in tumor progression. We initiated 25 mice of each transgenic line and 24 control mice twice with DMBA in a three days interval. Promotion of cell proliferation in skin through treatment with TPA was omitted in this experiment. However, the same tendency in tumor development as in the multistage carcinogenesis model was seen. Again, the timepoint of carcinoma appearance was earlier in the transgenic mice and the percentage of malignant tumors was higher in both transgenic lines. The ®rst carcinoma was seen in mice of line 114 seven weeks and in line 54 eight weeks after initiation. In contrast, the only carcinoma in wild-type mice appeared after 22 weeks. Mice of line 114 developed six carcinomas and eight carcinomas formed in mice of line 54 within 23 weeks after initiation ( Table 2) .
Expression of the dominant negative receptor from the transgene causes a resistance to the inhibition of proliferation by TGF-b in primary mouse keratinocytes. To assess the in¯uence of the dominant negative receptor in vivo we examined the BrdU incorporation in 8-week-old transgenic mice and in their nontransgenic littermates. Both, transgenic and nontransgenic mice displayed a similar number of labeled nuclei in untreated skin (Table 3) . Treatment with a single dose of TPA and assessment of the BrdU labeling indices after 18 h and 72 h showed that the BrdU-labeling indices increased in transgenic and nontransgenic mice in a similar way. But continuous promotion with TPA caused a signi®cantly higher chronic keratinocyte proliferation in the skin of transgenic mice as compared to non-transgenic mice. Mice of line 4 showed a 6 ± 7-fold increase and mice of line 54 an almost fourfold increase of labeled nuclei when compared to untreated skin. Non-transgenic control mice only had a twofold elevated labeling index (Table 3) .
Previous reports have shown that loss of TGF-b1 in benign papillomas is diagnostic for a high potential of malignant conversion. Immunohistochemical staining of early carcinomas of our transgenic mice using an anti-TGF-b1-antibody revealed expression of TGF-b1 Figure 5 Tumor induction in transgenic and non-transgenic mice. Twenty-six mice of each transgenic line and 24 control mice were initiated by topical treatment with DMBA followed by a tumor promotion protocol by topical application of TPA twice weekly. The per cent mice with carcinomas (A) respectively with tumors (B) is plotted versus time after initiation (weeks). Symbols represent the dierent groups as indicated in the ®gure. Note the early onset in carcinoma development and the high incidence (A). The development of all tumors showed a similar early onset in transgenics (B) in tumor cells (Figure 6a ). To investigate if also the type II receptor for TGF-b is present in early carcinomas of transgenic animals we stained for the endogeneous mouse type II TGF-b receptor ( Figure  6c ). Additionally, endogeneous type II TGF-b receptor expression was revealed in basal and predominantly in suprabasal cells of skin sections from transgenic and non-transgenic mice subjected to the initiation and promotion protocol. The outer root sheath of the hair follicles was also stained (Figure 6e and data shown).
Discussion
We report here the generation of transgenic mice expressing a dominant negative type II TGF-b receptor in the basal cell compartment of interfollicular epidermis and in the outer root sheath of hair follicles. Expression of the transgene is directed by the bovine keratin 5 promoter (Blessing et al., 1993; Casatorres et al., 1994; Ramirez et al., 1994) . Consistent with the previously described pattern of keratin 5 expression, transgene speci®c RNA is also detected in the respiratory tract, cervix, tongue and stomach (Moll et al., 1982) . In one transgenic line weak expression was also seen in kidney. Northern blot analysis revealed a strong overexpression of the transgene speci®c transcript of 2.4 kb length as compared to the endogeneous TGF-b type II receptor transcript of 4.4 kb length (Cui et al., 1995; Knaus et al., 1996) . Western blot analysis con®rmed that the transgene derived RNA which encodes a 286 aa polypeptide gives rise to a protein of 44 kDa. This compares well to the mass of the amino acids of the truncated receptor plus glycosylation to the same extent as it had been described for the wild type receptor (Lin et al., 1992) . Correct glycosylation seems to be important for the functionality of the type II receptor (Fafeur et al., 1993) . In both transgenic lines the dominant negative type II receptor interferes with TGF-b signaling in primary keratinocytes.
Despite the reduction of TGF-b mediated growth restriction, transgenic skin was phenotypically normal with no signs of hyperproliferation or aberrant dierentiation as judged from the normal distributions of keratins 1, 5, 6, and 10 (these authors, data not shown). By contrast, mice with a targeted deletion of the TGF-b1 gene showed hyperproliferation in the epidermis . In addition, TGF-b1 overexpression in the epidermis of transgenic mice may cause either an increase or a decrease of proliferation possibly depending on the pattern of transgene expression (Sellheyer et al., 1993; Cui et al., 1995) . Some explanation for these seemingly contradictory results can be provided by the notion that inhibition and promotion of proliferation through the three dierent TGF-b isoforms, TGF-b1, -b2, -b3, is balanced and that there may be a cross regulation between isoforms (Escherick et al., 1993) . In transgenic mice with a targeted deletion of the TGF-b1 gene signaling through TGF-b2 and TGF-b3 is still present and similarly, overexpression of TGF-b1 could also alter the expression of TGF-b2 and TGF-b3. Because all three isoforms of TGF-b utilize the type II receptor for signal transduction (Cheifetz et al., 1990; Sankar et al., 1995) , expression of a dominant negative receptor mutant suppresses signaling of all TGF-b isoforms. Thus, a phenotype evoked by disturbance of the Suppression of TGF-b signaling C Amendt et al balance of the three isoforms is avoided. The undisturbed normal skin in our transgenic mice suggests that TGF-b signaling is not crucial for maintaining homeostasis in basal and follicular keratinocytes in normal skin. Previously described transgenic mice expressing a dominant negative type II TGF-b receptor mutant in basal and suprabasal interfollicular keratinocytes develop hyperproliferative skin conditions in the absence of external stimuli (Wang et al., 1997) . Therefore, TGF-b signaling in suprabasal keratinocytes and not in basal cells may be more important for maintaining homeostasis in normal skin.
In skin treated with TPA both expression of TGFb1 and the type II TGF-b receptor is upregulated (Akhurst et al., 1988; Cui et al., 1995; Fowlis et al., 1996) . Therefore, it has been suggested that TGF-b plays an important role in skin carcinogenesis (Glick et Glick et al., 1994; Cui et al., 1996) . To elucidate the function of TGF-b signaling in tumor development we subjected our transgenic mice to skin carcinogenesis protocols (DiGiovanni, 1991; Hennings et al., 1993) . In a multistep initation-promotion protocol the transgenic mice developed carcinomas at an extremely early timepoint. The ®rst carcinoma was seen as early as 4 weeks after initiation. By contrast, no carcinomas arose in control mice within the ®rst 20 weeks of promotion. This is in full agreement with previously published carcinogenesis studies using this particular strain of inbred mice . Similarly, in studies where TGF-b was overexpressed in the skin resulting in an elevated malignant conversion frequency, the ®rst carcinomas were only seen after 15 weeks of promotion . Considering these previous reports, the extent of carcinoma development in our transgenic mice is remarkable. One reason may be the elevated proliferation rate in TPA promoted skin of transgenic animals and the reduced adaptation to TPA. TGF-b1 expression and endogeneous type II TGF-b receptor expression was present in the majority of early carcinomas derived from our dominant negative type II receptor transgenic mice. These results suggests that the carcinomas pro®t from tumor stimulating activities of TGF-b on stroma and angiogenesis (Roberts et al., 1986; FuÈ rstenberger et al., 1989; Cui et al., 1996; Oft et al., 1996) . The malignant cells escape TGF-b mediated growth restriction due to the presence of the dominant negative type II receptor allowing for a very rapid growth of these lesions. In the longterm TPA promoted skin from our transgenic mice and from wild-type mice endogeneous mouse type II TGF-b receptor is still upregulated in the epidermis and in the outer root sheath of the hair follicle. In previous reports it has been described that the type II TGF-b receptor is induced by single TPA treatment, but the expression declined 36 h after treatment (Cui et al., 1995; Fowlis et al., 1996) . Our result indicates that in longterm TPA treated skin TGF-b signaling through the type II receptor is still possible. In the mouse skin carcinogenesis model over 90% of papillomas and carcinomas initiated by DMBA have a speci®c A?T transversion in the codon 61 of the Harvey-ras gene (Balmain et al., 1984; . This mutation is sucient to initiate skin in vivo, but secondary events are necessary to induce the development of tumors Bailleul et al., 1990) . Our transgenic mice showed an increased malignant conversion frequency after initiation with DMBA without an ongoing exogeneous tumor promotion. This strongly suggests that a defect in TGF-b signaling can lead to an endogeneous tumor promotion. The dominant negative type II TGF-b receptor is able to provide the secondary genetic alteration beside the Harvey-ras mutation to induce carcinoma development. This agrees with a previous report using skin grafts of v-ras Ha initiated TGF-b1 null keratinocytes which produce squamous cell carcinomas (Glick et al., 1994) .
The extremely early onset of skin carcinoma development in our mice by suppression of TGF-b signaling in basal interfollicular cells and especially in hair follicle cells underlines the great importance of this pathway in skin tumor cell growth restriction. The high incidence of carcinomas in our transgenics is also consistent with the view that most carcinomas in this system arise from basal cells and possibly follicular cells, because the transgene is active in these populations (Miller et al., 1993) . Previous reports have shown that type II TGF-b receptor acts as a strong tumor suppressor gene, since mutations in the type II TGF-b receptor were found in several tumor types (Markowitz et al., 1995; Knaus et al., 1996) . Consistent with this ®nding transgenic mice overexpressing a dominant negative type II TGF-b receptor in lung and in the mammary gland developed an increased tumor incidence demonstrating the tumor suppressing activities of the type II TGF-b receptor (Bottinger et al., 1997) . Our results con®rm this assumption and suggest that the loss of TGF-b signal transduction by receptor mutations and not the disregulation of TGF-b expression is a rate limiting step in tumor progression.
Materials and methods

Generation of transgenic mice
The cDNA of the human type II receptor lacking the cytoplasmic kinase domain (DkTbRII) was inserted in the SalI site of the bovine cytokeratin III minilocus (human keratin 5) expression vector (Blessing et al., 1993; Brand et al., 1993) . The expression casssette was excised by KpnI digestion, gel puri®ed, and used for pronuclear microinjection of fertilized eggs of strain FVB/N essentially as described (Hogan et al., 1986) . Ospring was biopsied at ears or tails and analysed by PCR using a bovine keratin 5 (ATGAAGACAGCGTTTGCACCC) and a human type II TGF-b receptor speci®c oligonucleotide (TGCACTCAT-CAGAGCTACAGG) or Southern blotting using a bovine keratin 5 speci®c probe (Jorcano et al., 1984b; Lin et al., 1992) .
Northern blot analysis
Total RNAs from various tissues were isolated as described (Chomczynski and Sacchi, 1987) . Aliquots (approx. 15 mg) of RNA were electrophoresed on 1% agarose formaldehyde gels and subsequently blotted onto nylon membranes (Hybond N, Amersham, Braunschweig, Germany). Filters were processed at high stringency as described (Church and Gilbert, 1984) . As a hybridization probe the cDNA of the human truncated type II TGF-b receptor or exon 1 of the mouse type II TGF-b receptor were used (Lin et al., 1992; Oshima et al., 1996) . Both probes were approximately 700 bp and labeled with similar speci®c activity.
RT-PCR analysis
RT-PCR analysis was performed using pools of total cellular RNA from dierent tissues. Reverse transcription was accomplished using an RT-PCR kit according to the manufacturers instructions (Stratagene, LaJolla, CA, USA). PCR was performed using vent (exo-) DNApolymerase (New England Biolabs GmbH, Schwalbach/ Taunus, Germany) in 35 cycles. Primer pairs for both endogeneous BMP-6 speci®c RNA and transgene derived RNA were spanning introns. The primer pair used to detect endogeneous murine mRNA for BMP-6 consisted of primer mSPO2 located in exon 6 (ATGAATGCCAC-CAACCACG; position 110-128) and of the reverse primer mSPU2 located in exon 7 (GTTCGTGGTTTAAGGCAG; position 468-451) as deduced from the sequence of the murine gene for BMP-6 (Gitelman et al., 1997) . This primer pair produces a 268 bp diagnostic band at an annealing temperature of 618C when murine cDNAs are used as templates. The primer pair used to detect transgene derived mRNA consisted of primer Caf (GAAGAT-GACCGCTCTGACATC; positions 661-681) speci®c for the human dominant negative TGF-beta type II receptor cDNA and of the reverse primer K5-splice (GAGTA-GAAGCTGCTACTGCCG, position 383-363) speci®c for the bovine keratin 5 splice site as deduced from the sequences of these genes (Jorcano et al., 1984a; Lin et al., 1992) . This primer pair produces a 442 bp diagnostic band at an annealing temperature of 618C when cDNAs from appropriate transgenic tissues were used as templates.
In situ hybridization experiments
The transgene speci®c cDNA probe derived from the splice-and polyadenylation site of the bovine keratin 5 gene was generated by PCR. The primer pair consisted of primer K5-1 (5'-TATAGAATTCAGCAAGTTACTGCC-TCCC-3') and of primer K5-2 (5'-TATAAAGCTTAC-CAGGCTAGAGACTGGG-3') (Jorcano et al., 1984b) . Fragments were cloned into pGEM-4Z (Promega, Heidelberg, Germany) and digoxigenin-labeled sense and antisense RNAs were generated using in vitro transcription with SP6 and T7 RNA polymerases according to the suppliers protocol (Boehringer Mannheim, Mannheim, Germany). Cryosections were cut at 5 mm thickness and transferred onto polylysine coated DEPC-treated slides and ®xed immediately after sectioning in freshly prepared 4% paraformaldehyde in PBS for 20 min. Sections were acetylated in 0.1 M triethanolamine/0.2% acetic anhydride for 10 min, washed in PBS, dehydrated in graded ethanol and air dried. Prehybridization and hybridization were performed at 388C. The hybridization mixture contained 100 pg/ml digoxigenin labeled RNA, 50% deionized formamide, 8% dextrane sulfate, 46 SSC, 16 Denhardt's mixture and 0.5 mg/ml salmon sperm DNA. The slides were washed several times in 26 SSC, digested with RNAseA (20 mg/ml) for 30 min at 378C, washed three times in 60% deionized formamide/26 SSC at 388C and several times in Tris buer (100 mM Tris-HCl, 150 mM NaCl, pH 7.5) at room temperature. Sections were blocked for 30 minutes in 3% blocking mixture (Boehringer Mannheim) before incubation with anti-DIG AP-conjugated Fab-fragments (Boehringer Mannheim; 1 : 200 dilution in 3% blocking mixture) at room temperature for 2 h. Signal detection was according to protocols from Boehringer Mannheim by using NBT/BCIP as substrate. Endogeneous alkaline phosphatase was inhibited by addition of 1 mM levamisol to the substrate solution.
Western blot analysis
For Western blot analysis, proteins extracted from primary keratinocytes of transgenic and non-transgenic mice were separated by SDS ± PAGE and electroblotted onto PVDF membrane (Millipore, Eschborn, Germany). 1 mg/ml of a polyclonal antibody against the type II TGF-b receptor (H-567, Santa Cruz Biotechnology, Heidelberg, Germany) was used for detection. Immune complexes were visualized using a horseradish peroxidase-conjugated secondary antibody (Boehringer Mannheim, Germany) followed by chemiluminescence detection.
Chemical carcinogenesis
Each experimental group consisted of 23 ± 26 mice. Initiation and promotion were performed essentially as described (DiGiovanni, 1991; Hennings et al., 1993) . At the age of 8 weeks animals were shaved prior to topical application of 5 mg of TPA. Subsequently, initiation was performed with a single dose of 100 mg of 7,12-dimethylbenz[a]anthracene (DMBA) 18 h after TPA treatment. For tumor promotion animals were treated with TPA (2.5 mg), twice weekly. In a second protocol animals received two doses of DMBA (each 100 mg) in a three day interval without any further treatment. Development of lesions was monitored once weekly. Carcinomas were veri®ed histologically by ulceration and in®ltrative growth.
BrdU-labeling
BrdU-labeling experiments were performed using the`In Situ Cell Proliferation Kit, AP' (Boehringer Mannheim). Mice were injected with 30 mg of BrdU per gram body weight and sacri®ced after a labeling period of 1 h. Fixation and processing of the samples were performed according to the manufacturer's instructions. The number of labeled nuclei in the interfollicular epidermis was determined and related to 100 total basal cells. At least 600 cells were analysed for each animal and for each experiment values were obtained from three animals.
Primary cell culture and [
H]-thymidine incorporation
Primary keratinocytes were prepared from newborn transgenic mice and from their control littermates by ā otation procedure in dispase (0.1 g dispase/ml PBS) at 48C overnight (Kitano and Okada, 1983) . The keratinocytes were grown in MDCB 153 Medium (Seromed, Berlin, Germany) containing the following supplements: 0.05 mM Calcium, 0.3 ng/ml EGF (Sigma, Deisenhofen, Germany), 0.5 mg/ml Insulin (Seromed), 0.05 mg/ml hydrocortisone (Seromed), 7.5 mg/ml bovine pituitary extract (Sigma) and 3% dialyzed FCS (Drozdo and Pledger, 1993 ). For the [ 3 H]-thymidine incorporation assay the keratinocytes were plated in 24-well culture dishes at equal densities. Twentyfour-hours prior to addition of TGF-b the medium was replaced by serum-free medium supplemented with 0.2% BSA. Cells were labeled with 1 mCi/ml of [ 3 H]-thymidin for 3 h after preincubation with various concentration of TGF-b for 24 h. After one wash with PBS and three washes with ice cold 5% trichloroacetic acid the DNA was dissolved in 0.2 ml of 0.5 N NaOH and the signal quantitated in a scintillation counter (Zhao and Young, 1996) . For each concentration of TGF-b triplicates were counted.
Immunohistology
For TGF-b immunohistochemistry we used an anti-TGFb1 polyclonal antibody (Santa Cruz Biotechnology, Heidelberg, Germany, Cat. No. sc-146) at a 1 : 40 dilution. The cryosections were ®xed in 4% Paraformaldehyde in PBS for 20 min at room temperature. After preblocking with 1% BSA, 5% sheep serum, 0.5% Tween 20, 0.1 M MgCl 2 in 10 mM Tris-HCl (pH 7.4) the ®rst antibody was applied overnight at 48C. The secondary antibody was AP conjugated and used in a 1 : 200 dilution (Boehringer Mannheim, Germany, Cat. No 1214 632). As a control reaction normal rabbit serum was used at a concentration matching the immunoglobin content of the speci®c primary antibody. Mouse type II TGF-b receptor speci®c staining was performed with a polyclonal antibody raised against the carboxy-terminal peptide sequence as previously described (Moustakas et al., 1993; Henis et al., 1994) . After ®xing the sections in aceton at 48C for 10 min the sections were preblocked in 1% BSA, 5% FCS, 0.5% Tween 20, 0.1 M MgCl 2 in 10 mM Tris-HCl (pH 7.4). The mouse speci®c anti-type II TGF-b receptor antibody was used in a 1 : 250 dilution. The Secondary antibody was AP conjugated (Boehringer Mannheim) and used in a 1 : 700 dilution. As a control reaction preimmune-serum matching the immunoglobin concentration of the speci®c antibody was used. Both antibody incubations were performed at 378C for 60 min. Endogeneous phosphatase activity was inhibited by addition of 1 mM levamisol in the substrate solution.
